November 27, 2017 05:34 AM EST
R&D

With No­var­tis clos­ing in, Re­gen­eron scraps Eylea com­bo drug in a ma­jor set­back

John Carroll

Editor & Founder

Just a few weeks af­ter No­var­tis $NVS spelled out ex­act­ly why it be­lieves RTH258 can carve out a block­buster chunk of Re­gen­eron’s AMD mar­ket …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times